Centessa Pharmaceuticals (NASDAQ:CNTA) Now Covered by Analysts at TD Cowen

TD Cowen began coverage on shares of Centessa Pharmaceuticals (NASDAQ:CNTA) in a report published on Tuesday, Marketbeat.com reports. The firm issued a buy rating on the stock.

A number of other research firms have also weighed in on CNTA. Guggenheim increased their target price on Centessa Pharmaceuticals from $24.00 to $28.00 and gave the stock a “buy” rating in a research note on Friday, November 15th. BMO Capital Markets raised their target price on shares of Centessa Pharmaceuticals from $20.00 to $35.00 and gave the stock an “outperform” rating in a research report on Monday, September 16th. Morgan Stanley upgraded Centessa Pharmaceuticals from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $11.00 to $26.00 in a report on Thursday, September 19th. B. Riley began coverage on Centessa Pharmaceuticals in a report on Thursday, September 19th. They set a “buy” rating and a $33.00 price objective on the stock. Finally, Jefferies Financial Group upped their target price on Centessa Pharmaceuticals from $13.00 to $19.00 and gave the stock a “buy” rating in a report on Wednesday, September 11th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat, Centessa Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $25.83.

Centessa Pharmaceuticals Price Performance

Centessa Pharmaceuticals stock opened at $17.32 on Tuesday. Centessa Pharmaceuticals has a 12-month low of $6.65 and a 12-month high of $18.97. The company has a current ratio of 21.52, a quick ratio of 21.52 and a debt-to-equity ratio of 0.15. The firm has a 50-day moving average price of $16.93 and a 200-day moving average price of $14.30. The firm has a market capitalization of $2.28 billion, a PE ratio of -11.32 and a beta of 1.53.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.42) by $0.05. As a group, equities research analysts forecast that Centessa Pharmaceuticals will post -1.6 EPS for the current year.

Insider Buying and Selling

In other news, General Counsel Iqbal J. Hussain sold 77,705 shares of the firm’s stock in a transaction on Monday, December 16th. The stock was sold at an average price of $16.39, for a total value of $1,273,584.95. Following the completion of the sale, the general counsel now owns 125,785 shares of the company’s stock, valued at $2,061,616.15. This trade represents a 38.19 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Saurabh Saha sold 1,671 shares of the business’s stock in a transaction on Friday, November 22nd. The stock was sold at an average price of $18.24, for a total value of $30,479.04. Following the transaction, the chief executive officer now owns 575,661 shares in the company, valued at approximately $10,500,056.64. This trade represents a 0.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 368,023 shares of company stock worth $6,335,574 in the last three months. 11.59% of the stock is owned by insiders.

Institutional Investors Weigh In On Centessa Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the business. Mirae Asset Global Investments Co. Ltd. boosted its stake in Centessa Pharmaceuticals by 47.7% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company’s stock worth $40,000 after purchasing an additional 826 shares in the last quarter. GAMMA Investing LLC grew its holdings in shares of Centessa Pharmaceuticals by 103.1% during the third quarter. GAMMA Investing LLC now owns 2,972 shares of the company’s stock valued at $48,000 after buying an additional 1,509 shares during the last quarter. Quarry LP increased its position in shares of Centessa Pharmaceuticals by 47.8% in the 2nd quarter. Quarry LP now owns 9,608 shares of the company’s stock valued at $87,000 after acquiring an additional 3,108 shares during the period. Sandia Investment Management LP acquired a new stake in Centessa Pharmaceuticals during the 2nd quarter worth about $90,000. Finally, Fred Alger Management LLC purchased a new stake in Centessa Pharmaceuticals during the 2nd quarter valued at about $99,000. Institutional investors and hedge funds own 82.01% of the company’s stock.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.